[Effect of adrenergic beta-receptor blockaders on thrombocyte aggregation capacity in arterial hypertension].
The study of the aggregation capacity of platelets and the coagulation system of the blood by thromboelastography was undertaken in 36 patients with different forms of arterial hypertension. In 11 patients receiving obsidan these tests were repeated every 4-20 days. In patients with hypertension and pyelonephritis the aggregation capacity of platelets was enhanced, and in patients with glomerulonephritis it was not materially changed. All patients showed a shift in the food coagulation system toward moderate hypercoagulation, which did not change much with obsidan. A relationship between the blood pressure (BP) level and the functional properties of platelets was recorded. There was a simultaneous tendency to the decrease of BP and the inhibition of the aggregation capacity of platelets. Obsidan produces antiaggregation effect related to the decreased stability of platelet aggregates.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects; D005921:Glomerulonephritis / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D011433:Propranolol / Q000627:therapeutic use; D011704:Pyelonephritis / Q000188:drug therapy / Q000503:physiopathology; D013916:Thrombelastography
D000319:Adrenergic beta-Antagonists; D011433:Propranolol
Vliianie blokatorov beta-adrenergicheskikh retseptorov na agregatsionnuiu sposobnost' trombotsitov u bol'nykh arterial'noĭ gipertoniei.